Researchers track Jivi's safety over 4 years in hemophilia a patients
NCT ID NCT04461639
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 21 times
Summary
This study watches people with hemophilia A who are already using Jivi (a long-acting clotting factor) to prevent bleeding. Researchers will collect safety information during regular doctor visits for at least 4 years. No new treatment is given—just observation of real-world use. The goal is to learn about long-term side effects and how well the drug is tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Many Locations, Austria
-
Many Locations
Many Locations, Germany
-
Many Locations
Many Locations, Greece
-
Many Locations
Many Locations, Italy
-
Many Locations
Many Locations, Slovenia
-
Many Locations
Many Locations, Spain
Conditions
Explore the condition pages connected to this study.